TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
| Price | $4.55 |
|---|---|
| Market cap | $34M |
| Sector | Technology |
| Industry | Software - Application |
| Exchange | NASDAQ |
| 52-week range | 3.065-10 |
| Beta | 1.5 |
Explore TAOX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.